Ohio State Navbar

Research

Closed studies


Closed Research Studies:

SPRINT  - This is research opportunity for people who are concerned about their blood pressure.  This study is being conducted at The Ohio State University Medical Center to provide you with better blood pressure control through exams, testing and medication. 

 REWIND- Taking care of you heart  is important when you have type 2 diabetes.  That’s why we’re conducting REWIND, a clinical research study looking at an investigational drug given once- weekly to study the effects on heart disease and stroke in type 2 diabetes.  If you have type 2 diabetes, are at least 50 years old and are (or think you may be) at risk of these events,  please contact the study team to learn more about taking part. 

Diet-induced weight-loss study: Researchers at The Ohio State University Medical Center, Division of Endocrinology, Diabetes and Metabolism, are seeking participants to study the effect of diet-induced weight loss on high-density lipoprotein cholesterol (HDL-C) function (good cholesterol).

Diabetes Education and Lifestyle Intervention Program: Researchers at the Ohio State University Medical Center, Division of Endocrinology Diabetes and Metabolism, Diabetes Research Center are currently recruiting African Americans with type 2 diabetes to be involved in a 6 month diabetes education and lifestyle intervention program with follow-up for 2 years.

ACCORD study (Action To Control Cardiovascular Risk in Diabetes): It was designed to test the effects on major CVD events of intensive glycemia control, of fibrate treatment to increase HDL-cholesterol and lower triglycerides (in the context of good LDL-C and glycemia control), and of intensive blood pressure control (in the context of good glycemia control), each compared to an appropriate control. As one of the larger sites in The ACCORD trial, the DRC managed 214 participants for up to eight years.

Amgen 20070277: A Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Cinacalcet for the Treatment of Hypercalcemia in Subjects With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy.

DEFEND-1: Durable-response therapy evaluation for early or new onset type 1 diabetes; sponsor – Tolerx Inc.

Defend-2: Durable-Response Therapy Evaluation for Early- or New Onset Type 1 Diabetes. This is testing a new drug, Otelixizumab on preserving beta cell function in patient with new onset type 1 diabetes. Main inclusion criteria: 12-45 years of age; onset of type 1 diabetes < 90 days from the first dose of study drug; willingness to complete testing procedures including mixed-meal tolerance tests, eight day infusion of study drug, frequent follow up visits; frequent blood glucose testing. PI: Kwame Osei, MD

AWARD-1.A clinical trial sponsored by Eli Lilly is comparing the effects of a weekly injected antidiabetic agent or Exenetide on glycemic control in patients with type 2 diabetes on stable doses of metformin and pioglitazone.

Takeda: A phase IV, randomized, double-blind, placebo-controlled study to evaluate the effect of Pioglitazone compared to placebo on bone metabolism in impaired fasting glucose, postmenopausal women for one year of treatment.

Star 3: A prospective, randomized, two-arm study to compare the efficacy of the Medtronic MiniMed Paradigm real-time system versus Multiple Daily Injection (MDI) in subject with type 1 diabetes mellitus naive to insulin pump therapy.

ORIGIN : Outcome Reduction with Initial Glargine Intervention; Sponsor – Sanofi-Aventis Inc.

BEGIN-3583: A 52-week, randomized, controlled, open-label, multicenter, multinational, parallel, treat-to-target trial comparing efficacy and safety of SIBA and insulin glargine both administered once daily in a basal-bolus regimen with insulin aspart as mealtime insulin in subjects with type 1 diabetes. Sponsor: Novo Nordisk

BEGIN-3582: A 52-week, randomized, controlled, open-label, multicenter, multinational, parallel, treat-to-target trial comparing efficacy and safety of SIBA and insulin glargine both administered once daily in a basal-bolus regimen with insulin aspart as mealtime insulin ± treatment with metformin, ± pioglitizone in subjects with type 2 diabetes currently treated with insulin qualifying for intensified treatment. Sponsor: Novo Nordisk

 Type 2 Diabetes Studies: A research study sponsored by TECOS evaluating the investigational use of sitagliptin, to determine its effects on cardiovascular outcomes, is being conducted at The Ohio State University Medical Center.

Diabetes Heart Study: A research study on the effects of aspirin administration on good cholesterol and heart disease is being conducted at The Ohio State University Medical Center.

SAVOR (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus). A randomized, double blind, placebo controlled trial to evaluate the effect of saxagliptin on cardiovascular outcomes.

Minority Health Study: Trudy Gaillard, PhD, RN, is conducting research that focuses on the disparity of CVD in African-American and Caucasian women. Her current study will determine if aspirin increases the activity of PON1) in postmenopausal women and if it slows the progression of the thickening of the coronary arteries.
This is a pilot study that was supported by Award Number UL1RR025755 from the National Center for Research Resources, funded by the Office of the Director, National Institutes of Health (OD) and supported by the NIH Roadmap for Medical Research. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health.